Navigation Links
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol
Date:12/19/2013

nt of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursemen
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen Announces 2014 First Quarter Dividend
2. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
3. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
4. Amgens Third Quarter 2013 Revenues Increased 10 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 16 Percent To $1.94
5. Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Amgen and Onyx Pharmaceuticals Announce Early Termination of HSR Waiting Period for Amgens Acquisition of Onyx
8. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
9. Amgen To Participate At Citis 8th Annual Biotech Conference
10. Healthcare Briefing - Leading Medical Companies in the News: Bio-Solutions, Catalyst Pharmaceutical, MannKind, Amgen, Accuray
11. Amgen to Highlight New Data at Upcoming ESC Congress 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (Nasdaq: NKTR ) today reported its financial results ... Cash and investments in marketable securities at June 30, ... March 31, 2014."The second half of 2014 will be an ... milestones for a number of our late-stage clinical programs," said ... "The first of these is the potential US and EU ...
(Date:7/31/2014)...  UBM Medica US announces that Cancer ... presents exclusive slide shows dealing with communication in the ... care. Cancer Network, the online ... blogs, and podcasts about the latest clinical findings. Among ... , End-of-life care is challenging for even the ...
(Date:7/31/2014)... July 31, 2014  Decision Resources Group is launching ... product Marketrack to now include ChinaTrack; the new capabilities ... in an interactive dashboard providing detailed brand-level share tracking ... a hospital level. Other key capabilities of ... feed: In addition to end-user surveys of healthcare facilities, ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Swiss Exchange: CRX) today announced that following the end of ... Johnson & Johnson has acquired 98.89% of the issued Shares ... Crucell) and 98.93% of the issued and outstanding Shares in ...
... Cellceutix Corporation (Pink Sheets: CTIX ) today ... Agreement (CDA) pertaining to its anti-cancer drug, Kevetrin™, with ... Cellceutix CEO, Leo Ehrlich, commented, "It,s relatively uncommon ... a compound before clinical trials are underway.  The process ...
Cached Medicine Technology:Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 2Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 3Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 4Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 5Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 6Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs 7Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 2Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company 3
(Date:7/31/2014)... 2014) Women over the age of 65 face ... obesity, greater struggles against poverty and higher rates of ... the August issue of Annals of Allergy, Asthma ... College of Allergy, Asthma and Immunology (ACAAI), outlines the ... offers practical solutions to improve their care. ...
(Date:7/31/2014)... Alexandria, VA (PRWEB) July 31, 2014 ... Hilton hotel in Chicago, Illinois, the Mesothelioma Applied ... Chicago Medicine, will host a one-day regional ... members, covering a variety of topics related to ... , Some of the covered topics will include ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Leelanau Peninsula’s newest ... July 3, 2014 at 7788 East Horn Road in Lake ... Wine Trail , Aurora Cellars is the 25th winery along ... including the popular wine tour events, making its trail event ... 6-7, 2014. , Owners David and Faye Mathia opened ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary will ... on Monday, September 15, with its 2014 Opening Convocation, ... 3440 Shroyer Rd., Kettering, OH. Dr. Emma J. Justes, ... Emma Toussant Chair will speak on “Unexpected Undercurrents: Responding ... teaching and research interests include pastoral care and counseling, ...
(Date:7/31/2014)... Memphis, TN (PRWEB) July 31, 2014 In ... are required for proper storage of necessary life saving ... and staff. Unfortunately there is still a high number of ... is an EMT who steals the narcotics and even replaces ... urgent relief receives none. As seen in the case in ...
Breaking Medicine News(10 mins):Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:October Events: Regional Conference on Mesothelioma in Chicago 2Health News:October Events: Regional Conference on Mesothelioma in Chicago 3Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:United Theological Seminary to Open 144th Year 2Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2
... inheritable genes to enable people to produce more ‘perfect’ ... and on being human, warns a leading US science ... out great hope for IGM technology, which offers them ... Disease and schizophrenia on to their children.// ,However, ...
... the risk of pancreatic cancer in both sexes,while moderate ... obese individuals,says Dr. Dominique S. Michaud the head ... National Cancer Institute in Rockville, Maryland and colleagues collected ... 75 years of age, who participated in the Health ...
... popular belief, the heart can actually repair itself by growing new ... researchers in New York and Italy. Dr. Piero Anversa and colleagues ... heart muscle cells called myocytes continued to divide after a heart ... examined the hearts of 13 people who died within a few ...
... patients suffering from Angina may have some new treatment ... Angina, a common cardiovascular disorder affecting millions of people ... by blood vessels too clogged to get oxygen-rich blood ... either medication or for more serious cases, rerouting the ...
... piglets last week could significantly increase the success rate ... research has indicated that rejection of animal cells and ... to the presence of the gene alpha 1,3 galactosyl ... a sugar// to the surface of pig cells, flagging ...
... A new technique to keeping heart arteries flowing easily ... solving a major weakness of the common procedure.Doctors ... - the drug-coated stent. In testing on 30 patients ... percent effective, an accomplishment almost unheard of in medicine.// ...
Cached Medicine News:Health News:Perfect babies boon or a bane? 2Health News:Antibiotic, Gene Therapy Help Treat Angina 2Health News:Antibiotic, Gene Therapy Help Treat Angina 3Health News:Xenotransplantation “breakthrough” 2Health News:A ray of hope in Angioplasty dilemma 2
... WH, the latest in the Magnes line of ... and its full cortical coverage, provides the highest ... allowing study of a wide range of neuronal ... choice of detector configurations and can be equipped ...
... a non-invasive and painless method of stimulating ... Laboratories manufactures two magnetic stimulation devices, the ... (HSMS). The Hight Speed MES-10 ... up to 25 Hz at full power. ...
... MOBEE headboxes are the ... line of portable battery-powered ... a robust new mechanical ... software, XLTEK's standard MOBEE24plus ...
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: